Sasa veitchii extract protects against carbon tetrachloride-induced hepatic fibrosis in mice

Hiroki Yoshioka*, Tsunemasa Nonogaki, Shiori Fukaya, Yoshimi Ichimaru, Akito Nagatsu, Masae Yoshikawa, Hirohisa Fujii and Makoto Nakao

Abstract

Background: The current study aimed to investigate the hepatoprotective effects of Sasa veitchii extract (SE) on carbon tetrachloride (CCl₄)-induced liver fibrosis in mice.

Methods: Male C57BL/6J mice were intraperitoneally injected with CCl₄ dissolved in olive oil (1 g/kg) twice per week for 8 weeks. SE (0.1 mL) was administered orally once per day throughout the study, and body weight was measured weekly. Seventy-two hours after the final CCl₄ injection, mice were euthanized and plasma samples were collected. The liver and kidneys were collected and weighed.

Results: CCl₄ administration increased liver weight, decreased body weight, elevated plasma alanine aminotransferase, and aspartate aminotransferase and increased liver oxidative stress (malondialdehyde and glutathione). These increases were attenuated by SE treatment. Overexpression of tumor necrosis factor-α was also reversed following SE treatment. Furthermore, CCl₄-induced increases in α-smooth muscle actin, a marker for hepatic fibrosis, were attenuated in mice treated with SE. Moreover, SE inhibited CCl₄-induced nuclear translocation of hepatic nuclear factor kappa B (NF-κB) p65 and phosphorylation of mitogen-activated protein kinase (MAPK).

Conclusion: These results suggested that SE prevented CCl₄-induced hepatic fibrosis by inhibiting the MAPK and NF-κB signaling pathways.

Keywords: Carbon tetrachloride, Liver fibrosis, Sasa veitchii, Mitogen-activated protein kinase, Nuclear factor kappa B

Background

The liver performs important functions such as lipid metabolism, protein synthesis, and circulatory detoxification [1]. Acute or chronic hepatic injury can be caused by viral infections, non-alcoholic steatohepatitis, toxins, and alcoholism [2, 3]. The pathological progression of hepatic cell damage can result in fibrosis, cirrhosis, and ultimately hepatocellular carcinoma [4]. Hepatic fibrosis, a gradually progressing chronic liver disease, is a wound-healing response of the liver to repeated injury. Following acute injury, hepatocytes regenerate and replace necrotic or apoptotic cells, a process associated with inflammatory response. Hepatic fibrosis results from excessive accumulation of scar tissue following inflammation and liver cell death that occurs in most types of chronic liver disease.

Chronic exposure to carbon tetrachloride (CCl₄) is used to establish an experimental model of chronic liver disease, resulting in oxidative stress and hepatic injury. The mechanism of CCl₄-induced hepatotoxicity is well characterized [5] and is mediated by radicals generated by CYP2E1, such as trichloromethyl and trichloromethyl peroxy radicals. Increased oxidative stress mediated by reactive oxygen species (ROS) following CCl₄ exposure may play an essential role in progression of liver damage [6]. ROS induce tissue injury via lipid peroxidation and enhance hepatic fibrosis by increasing tissue levels of metalloproteinases inhibitors, resulting in increased collagen synthesis and accumulation [7]. Antioxidant compounds, such as polyphenols, are effective in the treatment of chronic hepatic damage and fibrosis [8, 9].
Polyphenols derived from plant extracts have demonstrated hepatoprotective properties [10, 11].

*Sasa veitchii*, of the family Gramineaeas, has been used in Asia as a health-promoting food and folk medicine. In Japan, its leaves are used as a food wrapping material or sushi sheet to prevent food from rotting. *S. veitchii* extract (SE) exhibits antioxidant, antitumor, anti-ulcer, anti-inflammatory, antimicrobial, antiviral, and anti-allergic activities [12–17]. These effects are attributed to C-glycoside flavonoids and phenolic acids, which are abundant in these extracts [18, 19]. In our previous study, we showed that SE reduced high-fat diet-induced obesity by modulating adipose differentiation and preventing hepatic steatosis in mice [20, 21]. In addition, SE confers protection against CCl4- and acetaminophen-induced acute hepatic injury in mice [22, 23]. Since obesity and CCl4- or acetaminophen-induced acute hepatotoxicity are commonly associated with inflammatory response, SE may have protective effects against other diseases with inflammatory components, such as chronic hepatitis.

To further characterize the therapeutic benefits of SE, we examined whether hepatitis induced by chronic exposure to CCl4 is prevented by treatment with SE.

**Methods**

**Preparation of SE**

Commercial, non-prescription SE was kindly provided by Sunchlon Co., Ltd. (Nagano, Japan). One milliliter of SE was made from 2.82 g of *S. veitchii* leaves according to the company data [23]. Chemical components of SE have been previously reported [22].

**Apparatus and chromatographic conditions**

Three-dimensional high-performance liquid chromatography (HPLC) analysis was performed using a JASCO series (JASCO Corporation, Tokyo, Japan) system consisting of a JASCO PU-2089 Plus pump and a JASCO MD-2010 Plus photodiode array detector. Chromatographic separation was performed using a YMC-Pack ODS-AL S-5 column (5 μm, 250 mm × 4.6 mm i.d., YMC Co., Ltd., Tokyo, Japan) controlled at 40 °C (Shimadzu CTO-20 AC, Shimadzu Corporation, Kyoto, Japan). The mobile phases consisted of acetonitrile (A) and 50 mM sodium dihydrogen phosphate monohydrate (B). Gradient elution was performed at a flow rate of 0.8 mL/min with the following parameters: 0–60 min A:B (10:90, v/v) to A:B (90:10, v/v), 60–75 min A:B (90:10, v/v), and 75–80 min A:B (10:90, v/v). The injection volume was 10 μL (0.2 mg/mL). Scan data were collected from 220 to 600 nm.

**Experimental protocol**

Twenty-four male C57BL/6J mice weighing 19–21 g and aged 6 weeks were purchased from CLEA Japan, Inc. (Tokyo, Japan). Mice were housed in a temperature- and humidity-controlled environment (24 ± 1 °C and 55 ± 5%, respectively) with a standard 12 h light/dark cycle (8:00/20:00) and provided with food and water ad libitum. This experiment was approved by the Institutional Animal Care and Experimentation Committee of Kinjo Gakuin University. After acclimatization to laboratory conditions for 1 week, the mice (7-week old) were randomly divided into 4 groups (6 mice each): (1) control group, (2) SE-treated group, (3) CCl4-treated group, and (4) SE + CCl4-treated group. In the CCl4 and SE + CCl4 groups, mice were intraperitoneally (i.p.) injected with CCl4 (1 g/kg (5 ml/kg) at 22:00 twice per week) for 8 weeks. The control and SE groups received i.p. injections of olive oil as placebo. Mice in the SE and SE + CCl4 groups were orally administered SE daily (0.1 mL at 10:00 every day) for the duration of the treatment course. Saline vehicle was orally administered to the control and CCl4 groups.

Body weight was measured weekly throughout the study. Mice were euthanized 72 h following the final CCl4 injection and bled by cardiocentesis to obtain plasma samples, which were stored at −80 °C until analysis. The liver and kidneys were weighed. In addition, separate liver samples were snap frozen in liquid nitrogen and stored at −80 °C or fixed in 15% neutral buffered formalin (pH 7.4).

**Plasma biochemical analysis**

Plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined using a Transaminase CII kit (Wako Pure Chemical Industries, Osaka, Japan), as previously described [24–26]. Plasma levels of tumor necrosis factor alpha (TNFα) were measured using a commercially available ELISA kit (eBioscience, San Diego, CA, USA), as previously described [22]. For relative quantification, calibration curves were prepared using standard solutions.

**Measurement of malondialdehyde and glutathione levels in the liver**

Total malondialdehyde (MDA) levels in the liver were measured using a colorimetric microplate assay kit for thiobarbituric acid reactive substances (Oxford Biochemical Research, Oxford, MI, USA), as previously described [24]. Glutathione (GSH) levels in the liver were examined using a GSSG/GSH quantification kit (Dojindo Laboratories, Kumamoto, Japan), as previously described [22].
Histopathological analysis
A portion of the left lobe of the liver from each animal was perfused with 15% phosphate-buffered neutral formalin (pH 7.4), dehydrated, and embedded in paraffin. Embedded tissues were sliced into 4-μm thick sections and stained with hematoxylin and eosin (H&E), as previously described [27, 28]. Liver fibrosis was quantified by using Masson’s trichrome (MT) staining according to the manufacturer’s protocol (ScyTek Laboratories, Inc., Logan, UT, USA). Necrosis area and aniline blue-positive area were calculated using ImageJ software (NIH). For immunohistochemistry staining, paraffin-embedded sections were deparaffinized and rehydrated in a graded ethanol series. Following antigen retrieval using proteinase K (Wako Pure chemical) and blocking of endogenous peroxidase using hydrogen peroxide (Wako Pure chemical), sections were incubated with rat anti-p65 monoclonal antibody (Santa Cruz, CA, USA) (1:160 dilution) as a primary antibody at 4 °C overnight (16 h). The sections were then incubated with a secondary antibody, anti-mouse IgG-FITC (MBL, Aichi, Japan) (1:160 dilution). In addition, sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) for nuclear staining.

Western blot analysis
Liver sections (80 mg) were homogenized in 720 μL ice-cold phosphate-buffered saline containing a phosphatase inhibitor and protease inhibitor (Nacalai Tesque, Kyoto, Japan) and centrifuged at 20,000 × g for 15 min at 4 °C. The supernatant from each sample was collected, and protein was extracted using a BCA protein kit (Nacalai Tesque). Protein samples (30 μg) were subjected to gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (BioRad, Hercules, CA, USA) and transferred to a polyvinylidene difluoride membrane using Trans-Blot Turbo Transfer System (BioRad). Next, the membrane was incubated with mouse anti-α-smooth muscle actin (anti-αSMA) monoclonal antibody (Santa Cruz), mouse anti-β-actin monoclonal antibody (MBL, Aichi, Japan), rabbit anti-c-Jun N-terminal kinase (JNK) polyclonal antibody, rabbit anti-phospho-JNK monoclonal antibody, rabbit-anti extracellular signal-regulated kinase (ERK) 1/2 monoclonal antibody, rabbit anti-phospho-ERK1/2 monoclonal antibody, rabbit-anti p38 monoclonal antibody, rabbit anti-phospho-p38 monoclonal antibody, peroxidase-conjugated anti-rabbit IgG (Cell Signaling Technology, Beverly, MA, USA), and peroxidase-conjugated anti-mouse IgG (BioRad) using previously described conditions [29]. Immuno-reactive bands were

---

**Fig. 1** 3D-HPLC of *S. veitchii* leaf extract (SE) and sodium copper chlorophyllin (SCC). Panels **a** and **c** indicate the 3D-HPLC fingerprint of SE and SCC, respectively. Panels **b** and **d** indicate the 2D-HPLC fingerprint at 254 nm of SE and SCC, respectively. Separation was achieved using a YMC-Pack ODS-AL S-5 column. The mobile phases consisted of CH₂CN (**a**) and 50 mM NaH₂PO₄ aq. (**b**); linear gradient elution was performed at a flow rate of 0.8 mL/min for 60 min AB = 1090 (v/v) to 90:10 (v/v) and followed by isocratic condition of B/A = 90:10 (v/v) for 15 min, then B/A = 1090 (v/v) for 5 min. The column oven temperature was held at 40 °C. Scan data were collected across the range of 220–600 nm.
visualized with an ECL system (BioRad). Band intensity was measured using ImageJ software (NIH).

**Statistical analysis**

Multiple comparisons were performed using one-way analysis of variance (ANOVA) with Tukey’s test. All statistical analyses were performed using SPSS Statistics for Windows software (version 24.0; IBM Corp., Armonk, NY, USA). Differences were considered statistically significant at \( p \) values < 0.05.

**Results**

**Analysis of SE by 3D-HPLC**

Typical chromatograms of SE and sodium copper chlorophyllin (SCC), the active ingredient of SE, are shown in Fig. 1. SCC eluted at a retention time of 63 min (Fig. 1c, d). However, various components in addition to SCC were present in SE (Fig. 1a, b). The broad peak in the SE chromatogram absorbed at 254 nm, suggesting the presence of organic compounds (Fig. 1b).

**Body weight change and organ weight**

We monitored change in body weight each week for 8 weeks. Throughout the experiment (from 1 week to 8 week), exposure to CCl\(_4\) significantly decreased body weight compared to control \((p < 0.01)\) (Fig. 2a). Not only absolute body weights but also body weight change was observed the same tendency (Fig. 2b). In contrast, body weight and body weight change in the CCl\(_4\) + SE group was significantly higher than that in the CCl\(_4\) group at 1,
2, 3, 4, 5, and 8 weeks. Body weight in the SE group was also significantly lower than that in the control group throughout the experiment including at 0 week. Since our previous study indicated that SE treatment for 2 weeks has no significant change on body weight in normal mice [21], lower starting body weight of mice in the SE group may be responsible for this difference. Therefore, we showed body weight ratios in Fig. 2b. Body weight in the control and SE groups continued to increase throughout the experiment, with overall changes of 118.7 ± 1.5 and 117.9 ± 2.3%, respectively. These data suggest that SE administration for 8 weeks did not significantly affect body weight change. In addition, the body weight changes in the CCl4 and CCl4 + SE groups correlated with body weight. These data indicated that SE may counteract body weight decreases induced by CCl4.

To examine the effects of SE and chronic exposure to CCl4 on organ weight, we measured the weights of the liver and kidney samples. The liver/body weight ratio was significantly higher (*p < 0.01*) in mice injected with CCl4 than control levels (Fig. 2c). In contrast, SE treatment alleviated CCl4-induced elevation of liver/body weight ratio (*p < 0.05*). Moreover, the kidney/body weight ratios of the four groups were not different (Fig. 2d). These data indicated that SE prevented CCl4-induced decreases in body weight and increases in relative liver weight.

### Plasma biochemical parameters and oxidative stress

As shown in Fig. 3, we determined plasma levels of several biochemical markers. Plasma levels of hepatic injury markers, ALT and AST, significantly increased following chronic CCl4 exposure, and this increase was attenuated by SE treatment (Fig. 3a, b, respectively).
In addition, we measured plasma TNFα, a marker of chronic hepatitis and inflammation [30, 31]. CCl4 administration for 8 weeks potentiated the levels of plasma TNFα, and SE treatment significantly attenuated this effect (Fig. 3c).

**Oxidative stress**

MDA is a marker of lipid peroxidation [32]. Hepatic MDA levels in the CCl4 group were significantly higher ($p<0.01$) than those in the normal control group (Fig. 4a). The SE treatment group had significantly lower ($p<0.01$) MDA levels than the CCl4 treatment group. In contrast, GSH, a major intracellular antioxidant [33], was significantly lower in the CCl4 treatment group than in the normal group (Fig. 4b). Although not significant ($p = 0.096$), treatment with SE attenuated CCl4-induced reduction of GSH levels in the liver.

**Histopathology**

Along with measurement of plasma biochemical parameters and hepatic oxidative stress, we conducted histopathological studies of liver tissues (Fig. 5). Liver sections of control (Fig. 5a) and SE (Fig. 5b) groups stained with H&E showed normal hepatic architecture. In contrast, the livers of CCl4-administered mice showed massive necrosis (62.1%) accompanied with microvesicular steatosis and mononuclear cell infiltration (Fig. 5c). Compared to the CCl4 group, hepatic injury was attenuated in the group treated with SE (17.4% necrotic) (Fig. 5d).

In addition, we observed collagen deposition in the tissues using MT staining. The livers from the control (Fig. 5e) and SE groups (Fig. 5f) showed normal hepatic architecture, with collagen fibrils visible only in the walls of adjacent blood vessels. In contrast, mice administered CCl4 for 8 weeks showed fibrotic scars within hepatic lesions, predominantly in the periportal areas, with early fibrotic septa developed as thin fibrotic strands (aniline blue-positive area was 4.3%) (Fig. 5g). In mice treated with SE, the area of collagen deposition was lower than that in the CCl4 group (aniline blue-positive area was 1.9%) (Fig. 5h).

**αSMA expression**

Expression levels of αSMA, a marker for hepatic fibrosis [34], were determined by immunoblotting (Fig. 6). Long-term CCl4 administration induced expression of αSMA, whereas SE treatment attenuated the CCl4-induced increase in hepatic αSMA expression. These results were consistent with histopathology results. In addition, similar results were observed using immunohistochemistry analyses (data not shown).

**Localization of p65**

Next, we evaluated the effect of SE on CCl4-induced p65 activation using immunohistochemistry (Fig. 7). A large proportion of p65 in the livers of the control (Fig. 7a) and SE groups (Fig. 7b) was localized in the cytoplasm. In contrast, the level of nuclear p65 significantly increased in the livers of mice injected with CCl4 (Fig. 7c). SE treatment inhibited the nuclear translocation of p65 (Fig. 7d).

**MAPK signaling pathway**

We determined the effects of SE on CCl4-induced hepatic mitogen-activated protein kinase (MAPK) signaling...
We confirmed p38, ERK, and JNK phosphorylation following 8 weeks of CCl₄ administration. Treatment with SE attenuated CCl₄-induced MAPK (p38, ERK, and JNK) phosphorylation. These results suggest that SE may prevent fibrogenesis by downregulating the MAPK signaling pathway.

Discussion

Hepatic fibrosis is a consequence of chronic liver damage associated with an increased morbidity rate and is considered a worldwide health risk [2, 35]. Therefore, prevention of chronic liver fibrosis is important to improve our quality of life. CCl₄ is the most commonly used toxin for inducing hepatic fibrosis in experimental models owing to the similarity of CCl₄-induced hepatic fibrosis to hepatic fibrosis in humans. Repeated exposure to CCl₄ is known to enhance fibrogenesis in hepatic tissues of mice [36]. CCl₄ is converted to trichloromethyl free radicals in the liver by CYP2E1, resulting in lipid peroxidation and liver injury [5]. In the current study, we established a hepatic fibrosis model through repeated exposure to CCl₄ and evaluated the protective effects of SE against hepatic fibrosis.

Oxidative stress is a major cause of hepatic fibrosis progression in experimental models [37]. Lipid peroxidation, a marker of oxidative damage, is associated with a wide range of diseases [38]. Moreover, oxidative stress promotes collagen synthesis by activated hepatic stellate cells (HSC) [39]. Increased levels of MDA, a product of lipid peroxidation, in hepatic tissues reflect oxidative stress in hepatic cells [32]. Therefore, many antioxidants have been investigated as preventive and therapeutic agents against CCl₄-induced hepatic fibrosis [40–43]. The present study showed that SE treatment decreased CCl₄-induced increases in ALT and AST levels, collagen deposition, and MDA production. These findings suggested that SE attenuated hepatic fibrosis through antioxidant activity, consistent with our previous study that reported the antioxidant property of SE [23].

HSCs are major fibrotic precursor cells that transdifferentiate to the extracellular matrix, producing myofibroblasts [34]. The present study showed that αSMA, a marker of the initiation phase of HSC activation, was elevated in the liver and was accompanied by bridging fibrosis. In addition, CCl₄-induced increases in αSMA were attenuated in the livers of mice treated with SE.
These results suggested that SE inhibited HSC activation during the pathogenesis of CCl₄-induced liver fibrosis. Increasing evidence indicates that inflammatory cytokines, such as TNFα, are critical to HSC activation in the pathogenesis of liver fibrosis [44]. Moreover, the relationship between NF-κB and inflammatory response is well characterized [45, 46]. NF-κB is sequestered in the cytoplasm by binding to IκB. In response to stress or pro-inflammatory stimuli, NF-κB translocates to the nucleus through translational inhibition of IκB [47]. Our present study showed that plasma levels of TNFα were significantly elevated in mice administered CCl₄. CCl₄-induced hepatic NF-κB nuclear translocation was inhibited in mice administered SE, indicating that the protective effect of SE was associated with decreased TNFα production and subsequent improvement of liver histopathology. These results suggested that SE suppressed CCl₄-induced HSC activation by inhibiting NF-κB activation and subsequent inflammatory response.

The MAPK family regulates cellular proliferation in response to cellular stresses and inflammation [48, 49]. Three distinct MAPK pathways have been reported in mammalian cells: the c-Jun N-terminal kinase (JNK) pathway, extracellular signal-regulated kinase (ERK) pathway, and p38 MAPK pathway. These three pathways are associated with HSC activation in the pathogenesis of hepatic fibrosis [50, 51]. Moreover, CCl₄ activates MAPK signaling [35, 42]. The present study showed that SE treatment attenuated CCl₄-induced phosphorylation of hepatic JNK, ERK1/2, and p38. These results suggest that SE inhibited CCl₄-induced hepatic oxidative stress, inflammatory response, and HSC activation by attenuating the activation of MAPK signaling.

Most studies, including ours, utilized an extract obtained from S. veitchii leaves, which are rich in bioactive compounds. The SE used in this study contained an abundance of SCC (250 μg/mL) [23], which exerts anti-inflammatory and antioxidant effects [52, 53]. Prior to this study, the active ingredient of SE had not been characterized. As such, we performed HPLC analysis to confirm the components of SE. A broad peak and a sharp peak were observed. The sharp peak corresponded to SCC contained in SE. Because the activities of SE are different from those of SCC, we speculated that the active ingredient of SE described in the present study is represented by the broad peak. Several antioxidant and anti-inflammatory compounds, such as polyphenols and flavonoids, have also been identified in S. veitchii [18, 54], indicating that these components may mediate the anti-fibrotic effects of SE. Since our present study was conducted using crude SE extracts, further investigation is needed to elucidate the active components of SE.

**Conclusion**

The present study showed that SE treatment prevented CCl₄-induced hepatic injury. Moreover, SE attenuated CCl₄-induced inflammatory response and subsequent HSC activation, hepatic NF-κB translocation, and MAPK signaling (Fig. 9). Hence, SE may have potential preventive/therapeutic potential for the treatment of hepatic fibrosis. Although repeated administration of CCl₄ was mimetic hepatic fibrosis model, our present investigation is valuable to contribute to self-medication options against chronic hepatic injury and disease.

**Abbreviations**

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CCl₄: Carbon tetrachloride; DAPI: 4′,6-Diamidino-2-phenylindole; ERK: Extracellular signal-regulated kinase; GSH: Glutathione; H&E: Hematoxylin and eosin; HPLC: High-performance liquid chromatography; HSC: Hepatic stellate cells; i.p.: Intraperitoneally; JNK: c-Jun N-terminal kinase; MAPK: Mitogen activated protein kinases; MDA: Malondialdehyde; MT: Masson’s trichrome; NF-κB: Nuclear factor kappa B; ROS: Reactive oxygen species; SCC: Sodium copper chlorophyllin; SE: Sasa veitchii extract; TNFα: Tumor necrosis factor alpha; αSMA: α-Smooth muscle actin

**Acknowledgements**

The authors thank Dr. Haruki Usuda (Shimane University, Japan) for his kind suggestions. We are grateful to Sunchlon Co., Ltd. for providing SE and compositional the data for SE.

**Funding**

This research was financially supported by Kinjo Gakuin University Research Grant.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
HY conceived and designed the experiments; performed the experiments; analyzed and interpreted the data; contributed reagents, materials, and analysis tools or data; and wrote most of the paper. TN performed the experiments; analyzed and interpreted the data; contributed reagents, materials, and analysis tools or data; and wrote the paper in part. SF performed the experiments and wrote the paper in part. AN performed the experiments, analyzed and interpreted the data, and contributed reagents. MY contributed reagents, materials, and analysis tools or data. MN contributed reagents, materials, and analysis tools or data. All authors read and approved the final manuscript.

Ethics approval
All experiments were approved by the Institutional Animal Care and Experimentation Committee of Kinjo Gakuin University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 2 August 2018 Accepted: 1 October 2018

Published online: 15 October 2018

References
1. Gowda S, Desai PB, Hull W, Math AA, Vemekar SN, Kulkami SS. A review on laboratory liver function tests. Pan Afr Med J. 2009;3:17.
2. Jiang JX, Toook NJ. NADPH oxidases in chronic liver diseases. Adv Hepatol. 2014;2014. PMID: PMC4591547. PMID: 26436133.
3. Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol. 2003;38(Suppl 1):S58–53.
4. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028–40.
5. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of halokalanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003;33:105–36.
6. Al-Rasheed NM, Faddah LM, Mohamed AM, Mohammad RA, Al-Amin M. Potential impact of silymarin in combination with chlorogenic acid and/or melatonin in combating cardiomyopathy induced by carbon tetrachloride. Saud J Biol Sci. 2014;21:205–74.
7. Blomhoff R. Dietary antioxidants and cardiovascular disease. Curr Opin Lipidol. 2005;16:647–54.
8. Kim HK, Yang TH, Cho HY. Antifibrotic effects of green tea on in vitro and in vivo models of liver fibrosis. World J Gastroenterol. 2009;15:5200–5.
9. Fadhel ZA, Amran S. Effects of black tea extract on carbon tetrachloride-induced lipid peroxidation in liver, kidneys, and testes of rats. Phytother Res. 2002;16(Suppl 1):S28–32.
10. Domitrovic R, Jakovic H. Antifibrotic activity of anthocyanidin delphinidin in carbon tetrachloride-induced hepatotoxicity in mice. Toxicology. 2010;272(1–2):1–10.
11. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther. 2002;95:667–202.
12. Usuda H, Fuji H, Nonogaki T. Sasa veitchii extract suppresses 2,4-dinitrofluorobenzene-induced contact hypersensitivity in mice. Food Agricol Immunol. 2016;27:523–34.
13. Yoshida M, Hida TH, Takeda H, Tsuboi M, Kanamori M, Akachi N, et al. Effect of Sasa veitchii extract on immunostimulating activity of beta-glucan (β-GC) from culinary-medicinal mushroom Sparassis crispa Wulf.f. (higher basidiomycetes). Int J Med Mushrooms. 2012;14:537–47.
14. Okada Y, Okajima H, Takahashi K, Kanamori M. Kinetic study of Sasa veitchii extract as a radical scavenger and an antioxidant. J Food Sci. 2012;77: C1211–7.
15. Iwata K, Naito E, Yamashita K, Kakino K, Taharaguchi S, Kimachi Y, et al. Antipseudobacteria virus activity of kumazasa extract. Biocontrol Sci. 2010;15:123–8.
16. Sakai A, Watanabe K, Koketsu M, Akuwazawa K, Yamada R, Li Z, et al. Anti-human cytomegalovirus activity of constituents from Sasa albo-marginalana (Kumazasa in Japan). Antivir Chem Chemother. 2008;19:125–32.
17. Ren M, Reilly RT, Sacchi N. Sasa health exerts a protective effect on Her2/NeuNR mammary tumorigenesis. Anticancer Res. 2004;24:2879–84.
18. Zhang Y, Jiao J, Liu C, Wu X, Zhang Y. Isolation and purification of four flavone C-glycosides from antioxidant of bamboo leaves by macroporous resin column chromatography and preparative high-performance liquid chromatography. Food Chem. 2008;107:1326–36.
19. Nakajima Y, Yun YS, Kunugi A. Six new flavonolignans from Sasa veitchii (Carr.) Rehder. Tetrahedron. 2003;59:8011–5.
20. Yoshioka H, Mori M, Yoshihawa M, Fuji H, Nagatsu A, Nonogaki T. Suppressive effect of <i>C. Sasa veitchii</i> extract on obesity induced by a high-fat diet through modulation of adipose differentiation in mice. Fundam Toxicol Sciences. 2017;4:261–8.
21. Yoshioka H, Mori M, Fuji H, Nonogaki T. Sasa veitchii extract reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Nagoya J Med Sci. 2017;79:279–90.
22. Yoshioka H, Usuda H, Fuji H, Nonogaki T. Sasa veitchii extract suppresses acacetaminophen-induced hepatotoxicity in mice. Environ Health Prev Med. 2017;22:54.
23. Yoshioka H, Tanaka M, Fuji H, Nonogaki T. Sasa veitchii extract suppresses carbon tetrachloride-induced hepatoto- and nephrotoxicity in mice. Environ Health Prev Med. 2016;21:554–62.
24. Yoshioka H, Nonogaki T, Fukushima N, Shinohara H, Hwang GW, Ohtani K, et al. Chonotoxicity of bromobenzene-induced hepatic injury in mice. J Toxicol Sci. 2017;42:251–8.
25. Yoshioka H, Usuda H, Nonogaki T, Onosaka S. Carbon tetrachloride-induced lethality in mouse is prevented by multiple pretreatment with zinc sulfate. J Toxicol Sci. 2016;41:55–63.
26. Miura N, Ohtani K, Hasegawa T, Yoshioka H, Hwang GW. High sensitivity of testicular function to titanium nanoparticles. J Toxicol Sci. 2017;42:359–66.
27. Yoshioka H, Fukuya S, Fukushima N, Nagatsu A, Nonogaki T, Onosaka S. Bromobenzene-induced lethal toxicity in mouse is prevented by pretreatment with zinc sulfate. Chem Biol Interact. 2016;254:117–23.
28. Miura N, Yoshioka H, Ashimori A, Ohtani K, Hasegawa T, Hwang GW, et al. Multidirectional analyses of hepatic chonototoxicity induced by cadmium in mice. J Toxicol Sci. 2017;42:597–604.
29. Yoshioka H, Ichimaru Y, Fukuya S, Nagatsu A, Nonogaki T. Potentiating effect of acacetaminophen and carbon tetrachloride-induced hepatotoxicity is mediated by activation of receptor interaction protein in mice. Toxicol Mech Methods. 2018;28:615–621.
30. Leandro G, Angia M, Hui J, Fabris P, Rubbia-Brandt L, Colloro G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–42.
31. De Groot J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulis E, et al. Classification of chronic hepatitis. Lancet. 1995;345:2461–98.
32. Draper HH, Hadley M. Malonaldehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421–31.
33. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thenvenin M, Jaudon MC, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med. 1996;21:845–53.
34. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–56.
35. Shu M, Zhang Y, Zhang S. Inhibition of MAPK and NF-kappaB signaling pathways alleviate carbon tetrachloride (CCL4)-induced liver fibrosis in Toll-like receptor 5 (TLR5) deficiency mice. Biochem Biophys Res Commun. 2016;471:233–9.
36. Takamatsu H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis. 1990;10:106–65.
37. Poll G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Asp Med. 2000;21:49–98.
38. Xie H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997;82:291–5.
39. Lee KS, Buck M, Houglim K, Chojkier M. Activation of hepatic stellate cells by TGF-alpha and collagen type I is mediated by oxidative stress through c-rmb expression. J Clin Invest. 1995;96:2461–8.
40. Shrestha N, Chand L, Han MK, Lee SQ, Kim CY, Jeong YI. Glutamine inhibits CCl4-induced liver fibrosis in mice and TGF-beta mediated epithelial–mesenchymal transition in mouse hepatocytes. Food Chem Toxicol. 2016;93:129–37.
41. Hafez MM, Al-Harbi NO, Al-Hosaini KA, Al Shari SD, Al Rejaie SS, et al. Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats. Biol Res. 2015;48:30.
42. Wang QJ, Chen X, Zhang C, Tao L, Zhang ZH, Liu XQ, et al. Phenylbutyric acid protects against carbon tetrachloride-induced hepatic fibrogenesis in mice. Toxicol Appl Pharmacol. 2013;266:307–16.
43. Ilavenil S, Kaleeswaran B, Ravikumar S. Protective effects of lycorine against carbon tetrachloride induced hepatotoxicity in Swiss albino mice. Fundam Clin Pharmacol. 2012;26:393–401.
44. Son G, Imuro Y, Seki E, Hirano T, Kaneda Y, Fujimoto J. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCH-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2007;293:G631–9.
45. Kim SH, Johnson VJ, Shin TY, Sharma RP. Selenium attenuates lipopolysaccharide-induced oxidative stress responses through modulation of p38 MAPK and NF-kappaB signaling pathways. Exp Biol Med (Maywood). 2004;229:203–13.
46. Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants. Nutrition. 1996;12:274–7.
47. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature. 1997;385:540–4.
48. Moon H, Lee B, Choi G, Shin D, Prasad DT, Lee O, et al. NDP kinase 2 interacts with two oxidative stress-activated MAPKs to regulate cellular redox state and enhances multiple stress tolerance in transgenic plants. Proc Natl Acad Sci U S A. 2003;100:6358–63.
49. Park RM, Kammers C, Vaysier-Taussat M, Chen A, Bonventre JV. Prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction. J Biol Chem. 2002;277:20400–9.
50. Lv Z, Xu L. Salvianolic acid B inhibits ERK and p38 MAPK signaling in TGF-beta1-stimulated human hepatic stellate cell line (LX-2) via distinct pathways. Evid Based Complement Alternat Med. 2012;2012:960128.
51. Kluske J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Österreicher CH, et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology. 2010;138:347–59.
52. Subramoniam A, Asha W, Nair SA, Sadasivarao SP, Suresh Kumar PK, Rajendran KN, et al. Chlorophyll revisited: anti-inflammatory activities of chlorophyll a and inhibition of expression of TNF-alpha gene by the same. Inflammation. 2012;35:959–66.
53. Serpeliomi JM, Grotto D, Aissa AF, Mercadante AZ, Bianchi Mde L, Antunes LM. An evaluation, using the comet assay and the micronucleus test, of the antigenotoxic effects of chlorophyll b in mice. Mutat Res. 2011;725:50–6.
54. Hayashi K, Lee J-H, Kurosaki Y, Nozawa M, Asai S, Takehita K, et al. Evaluation of fractions and isolated polysaccharides from Sasa veitchii for their preventive effects on influenza a virus infection. J Funct Foods. 2014;10:25–34.